ABPA) complicates asthma and may lead to
chronic pulmonary aspergillosis (CPA) yet global burdens of each have never been estimated.
Antifungal therapy has a place in the management of ABPA and is the cornerstone of treatment in CPA, reducing morbidity and probably mortality. We used the country-specific prevalence of asthma from the Global Initiative for Asthma (GINA) report applied to population estimates to calculate adult asthma cases. From five referral cohorts (China, Ireland, New Zealand, Saudi Arabia and South Africa), we estimated the prevalence of ABPA in adults with asthma at 2.5% .
In ABPA case series, pulmonary cavitation occurred in 10%, allowing an estimate of CPA prevalence worldwide of 193 million adults.
With active asthma worldwide, we estimate that 4,837,000 patients develop ABPA.
By WHO region, the ABPA burden estimates are:
- Europe, 1,062,000;
- Americas, 1,461,000;
- Eastern Mediterranean, 351,000;
- Africa, 389,900;
- Western Pacific, 823,200;
- South East Asia, 720,400.
We calculate a global case burden of CPA complicating ABPA of 411,100 at a 10% rate with a 15% annual attrition.
The global burden of ABPA potentially exceeds 4.8 million people and of CPA complicating ABPA ˜ 400,000, which is more common than previously appreciated. Both conditions respond to antifungal therapy justifying improved case detection.
Prospective population and clinical cohort studies are warranted to more precisely ascertain the frequency of ABPA and CPA in different locations and ethnic groups and validate the model inputs.
Original paper read here